And glew called that a dump ??????
ROFL, the short and distort campaign shows how desperate shorts are?
They'll say anything to make a buck
When you are squeezed, like the shorts were last year, don't cry too much ;..(
Thanks for the info that explains why you can get a six dollar stock for one. Now the trick is to hold it long enough to watch it get back there. Your shorts are certainly all over this like a golden calf with fleas. Another run above two will certainly get rid of the overnight ones but it’s going to take a lot more to get rid of the ones who bought at twice this. Any idea when we’ll get a progress report on the state of the integration?
Try $250 instead of $250k and you might be right. Chuck is back in school so don’t expect him to be back until the weekend or spring break. He’s not a major holder and never will be. If you want to watch the actions of anyone then check out the SEC documents for Matthew Strobeck. He accumulated hundreds of thousands of shares last year and it wouldn’t surprise me to see him add more this year. Insiders have an edge we don’t; they know what is B$ and what isn’t and they have only one reason to buy.
Dec 18, 2012 - "Metabolix, Inc. (MBLX), an innovation-driven bioscience company focused on delivering sustainable solutions for plastics, chemicals and energy, today announced that I6001, a biobased polymeric modifier for PVC (polyvinyl chloride) formulations based on Metabolix PHA resin, is now available for shipment to customers. Metabolix designed I6001 as a performance additive to improve the mechanical and environmental performance characteristics of PVC. With a diverse use pattern ranging from construction materials to medical applications, PVC has an estimated market demand of approximately 35 million metric tons per year.
Metabolix researchers recently developed a series of PHA-based polymeric modifiers and presented data demonstrating very good miscibility with PVC and significant improvements in the modification and processing of PVC. Based on these findings, Metabolix developed I6001 polymeric modifier which significantly improves impact resistance and toughness in rigid and flexible PVC applications without compromising PVC transparency or UV stability. I6001 also may serve as a PVC processing aid due to its excellent miscibility and shear melting with PVC. Additional benefits of I6001 include plasticization, low modifier volatization and low extractables. I6001 is 85 percent biobased and is now available commercially.
Metabolix is developing a series of second generation products in the modifier space which the Company plans to launch in 2013 in conjunction with the planned start-up of PHA biopolymer manufacturing in Spain."
Sentiment: Strong Buy
My neighbor’s brother just hear from his sister that their dentist heard from his gardener that his sister heard from her janitor that this stock is consolidating before another run-up and that the shorts here are in trouble... Oh boy!
I love ready’s sale pitch for this stock, kmmm, ummm, hmmm , If insiders won’t buy at this level then it must not be worth buying. Of course, that’s a very reasonable argument if you are trying to support a short position but it excludes the possibility that insiders can’t buy right now.
And of course jeff has the same exact reasoning. If management won’t buy at these ridiculous levels then I’ll never say anything positive about this company. Abandon all hope ye who enters the position! Once again, we don’t have enough information about management’s ability to buy or sell this stock. All we know is that insider activity has disappeared since June (and yes that may tell you something) and that the only one who’s been active is Matthew Strobeck who is somehow getting his shares for free. What’s that all about anyway, right???
Brocha, I recognize your courage in buying 1500 shares today which is why I’ve bought a block too. The company has assets worth much more than today’s ridiculous price and it made a very smart move teaming with Antibioticos.
Shortman and everyone else who’d love to see insiders buying, I agree 100% with you but that’s not always possible. Of course, that doesn’t prevent someone new from walking up to the plate.
Good luck to all!
Sentiment: Strong Buy
Re: Who is buying all this stock 27 million shares at 16.45
Answer: Folks gambling on significant upside and shorts trying to get out so they can move on
Re: "Maybe another offer coming in...."
You could be right, but how much higher? $18... $20.... What would it take to make it a done deal
If PCP sees or hears from enough unhappy shareholders they may try to make it right and give a little more. I'd gladly sell my shares for $18 but wouldn't mind object to more :)
Shorts are now in trouble cause its time to get out or face the music
You have a very powerful short community pushing on a stock that is selling below cash. If longs here could see and properly explain why this stock is worth more than what it is currently priced at then you could see a very bullish run. But no one here is able to do that, instead they all have reasons why they think top management should be fired. You fire top management and then the real discount begins. If you want to see your investment increase in value then everyone here needs to start explaining why they believe this is a good investment. If you can't do that then you should really move on because the shorts are ruling through greed and fear and without a proper logical reason to buy fear is ruling the day.
They have created an artificial down trend. The chart along is enough reason for most longs to stay away. The only way that trend is going to break is for buyers to return. Can you give them reasons to buy? If so, I've never seen it.
I'm sure Jamba has a good plan, but it might help to study the plan of their competition...
From recent press:
Smoothie King plan to grow in a market that seems crowded already? In a recent interview from headquarters, Kim shared his battle plan for smoothie domination:
Add food in the U.S. Kim pioneered a salad-and-wraps menu for the Korean stores that he plans to test and bring to the U.S. units. Right now, American stores sell little food — just the odd energy bar. Adding more of a lunch menu offering “healthy portable meals on the go” could help grow existing-store sales. At the Korean stores, more than one-fifth of revenue comes from food.
Open company stores. Plans are to open 200 company-owned stores (currently there is only one company unit) over the next five years. These stores would become the testing ground for new initiatives, including the food. The company may also explore new store formats — the Korean stores are larger and have more seating. “These will be flagship stores that show we’re an ‘A’ brand,” says Kim, “not a ‘B’ or ‘C’ one.”
Explode domestic franchising. Kim hopes to open 800 franchised units over the next five years.
Emphasize health. Rather than just another smoothie store, Smoothie King’s focus is on the health benefits and low calories in its drinks (many are around 300 calories). Kim says this approach builds more customer loyalty than positioning smoothies as a treat. Current tagline on the website: “Be good to yourself.”
Stay where it’s warm. Having watched the misadventures of other smoothie chains that expanded to cold-weather regions only to end up pulling back, Kim expects to focus most expansion in the southern U.S. First targets for expansion include Dallas and Miami.
Grow overseas. The company is also looking to increase its presence in Asia. Its first Singapore store — a showy flagship in a Times Square-like location — opens in December, and expect to see more units in the region next year.
Revamp marketing. In the past, Kim says Smoothie King suffered from “too many messages” in its advertising. The company has retained WD Partners to work on strategy and branding efforts. Expect an upcoming campaign to focus on nostalgia for the brand. “Some people have been coming here all their lives,” Kim notes.
Dominate in social media. Smoothie King customers are engaged with the brand on Facebook, where a recent sweepstakes contest the chain ran garnered 4,725 responses and a big chunk of new Facebook fans. The company has a ways to go here — Jamba Juice has 1.5 million fans compared with Smoothie’s quarter-million.
Sentiment: Strong Buy
This sounds really good as it expands opportunities for Metabolix:
"Metabolix developed a series of PHA copolymers and demonstrated that they were miscible with PVC resins. Based on miscibility and performance requirements, Metabolix researchers created specific compositions of PHA copolymers to improve plasticization, impact and processing modification of rigid and flexible PVC.
In plasticization, PHA copolymers performed as high molecular weight, readily dispersible plasticizers and enabled formulation of compounds with low additive migration, low extractables, volatile loss and staining.
* In impact modification, PHA rubber copolymers outperformed the best available MBS core/shell impact modifiers and did not compromise PVC transparency or UV stability.
* As a processing aid, the metal-adhering properties of PHA copolymers promoted homogeneous shear melting of PVC particles and prevented overheating and degradation.
* Together, the results demonstrate that these newly developed biobased PHA copolymers can produce significant improvements in the modification and processing of PVC.
“The significant performance benefits PVC gained from blending with PHA copolymers underscores the versatility and value of Metabolix’s PHA technology,” said Oliver Peoples, chief scientific officer and vice president of research at Metabolix. “These developments will allow us to broaden the addressable market opportunity for our materials, beyond our traditional focus on those markets requiring biodegradation.”
Sentiment: Strong Buy
Jos, the stock price is picked by the market and unfortunately there’s nothing we can do about that. The shorts have taken control of this stock and they are using greed, uncertainty and fear in their attempts to drive down the price. Right now they are also taking advantage of low end of the day volumes; dumping small quantities of shares at rock bottom prices to create and accelerate an artificial down trend. Even though their actions verge the edge of being illegal, there’s probably nothing we can do to stop it… Of course, there’s always something we can do, but most here have lost the will to help (that includes...)
Eno might be able to strengthen the public’s perception of Metabolix by sharing more about the progress being made at Antibioticos. The idea of a blog showing teams working together, progress being made, and a friendly working environment is a good one. Unfortunately, he appears to be working on Metabolix’s reputation by delivering monthly presentations but the turnouts are rather sparse.
What would you suggest that Eno do to turn things around? Some have suggested that he give up control of the Americas to a deep pockets partner (isn’t that what ADM was)? Others have suggested that he give up, sell the company’s assets and walk away; is that what you really want?
I see plenty of potential with what Eno is doing with Antibioticos and clearly they do too or they wouldn't be working with him. If that’s not enough to keep the share price at cash value (not including the value of the product reserves, patents, etc.) then I don’t know what will. Perhaps the best thing we can do here is give the shorts a run for their money. Save all of our purchase orders until the end of the day then buy up all of the cheap shares that they want to unload. Visit the websites and bb’s of several major North American companies and lay out the case for purchasing Metabolix for their portfolios. Determine if you see a future here and if so then lay out that future for new investors wherever and whenever possible.
Rather than cry about Eno’s past failures, look for ways this can and will turn around. Do you see any future with Antibioticos or is it simply a money pit waiting to burn up whatever cash we have left?
Sentiment: Strong Buy
Jos, they are busy collaborating with Antibioticos towards the goal of producing commercial grade Mirel biopolymer resin. They picked Antibioticos because it is a successful highly regarded toll manufacturer of fermentation products (in business for over 50 years) and because they already have manufacturing equipment very well suited to the production of Mirel resin. IMHO, Eno choose very well, rather than spend years and hundreds of millions building everything from the ground up they are able to bootstrap off a world class facility by adding a minimal amount of new equipment. FYI, this is perhaps one of the best decisions that Eno has ever made.
Jos, you appear to be asking, what is the delay? This is what they are now working on and they expect to show sample from by early next year (unfortunately it takes time):
“At Antibióticos, the fermenters are already in place as is much of the recovery equipment. As we prepare for the contract manufacturing phase our anticipation is that we will need to secure a limited amount of additional recovery equipment which we believe we can do at short lead time and a relatively low capital cost. We will be working with Antibióticos to finalize the details of the contract manufacturing arrangement and to map out the details of the required capital investment as we work together under the demonstration phase of the LOI in the coming months.”
Many of us keep asking about their bio chemical business; this appears to be Eno’s answer for that (it will be looked at right after Mirel is back in production):
“Working with Antibióticos enables Metabolix to collaborate with a highly capable partner and maintain control of all aspects of our technology and process. It allows us to stay flexible, to work with multiple partners, to deploy new technology when we see fit and to integrate biopolymers and chemical manufacturing in the future.”
Some of us are worried about funding growth and it’s pretty clear that Eno is too. Clearly at some point this company is going to need help and while that will most certainly dilute existing shareholders it will also add cash that strengthens the company so that growth becomes possible:
“While we anticipate the capital cost being modest and manageable for Metabolix we can now choose to open conversations if we wish with a number of customers who had expressed an interest in investing with us in PHA manufacturing.”
Eno is focused on keeping Metabolix healthy and growing but it is going to take time and patience:
“It is much too early to offer any guidance on the earnings potential from on the Antibióticos facility, but our analysis and collaborative relationship with Antibióticos should allow this to be cash generator for Metabolix once the business is ramped up. While it should be clear to you that we are enthused about the potential of the Mirel launch we are well aware of the many challenges in front of us and are working aggressively to overcome them”
Patience is the key to holding a speculative investment
Sentiment: Strong Buy
Zero debt + product reserves + cash + LOI == Time
Eno is not in control of the stock… Weak handed investors are the ones giving up their shares at a discount. If you want to blame anyone blame everyone who doesn’t have the patience to wait. Eno told you that he’s found what he believes is the very best place to manufacture Mirel. Now he and his company are doing everything they can do to make that happen. The falling stock price is caused by uncertainty. Eno could certainly help that a little by creating a blog, adding a few pictures of the two teams working together, telling a few stories about the bumps and successes along the way and keeping investors informed. If you are waiting for a big press announcement saying that the first successful test runs have occurred then you are probably going to be waiting quite awhile; the conference call mentioned something about early next year. That’s a long time to wait for nervous short term investors but it is a drop in the bucket for patient long term investors.
The daily water torture that is the Metabolix stock is hard, but the problem isn’t Eno… It is the savvy shorts who drop the price at the end of the day by dropping a few hundred shares at the very last second. It is also weak handed investors who are patient enough to hold on or at least ask for more.
I need to move some of my funds around, if you are considering purchasing IBKR right now, yet you would like to delay your purchase for a few months, then please consider looking at the January $10.71 options. I’m not going to sell mine at a loss but I am asking $4.10 (a 9 cent premium to delay your purchase by nearly three months isn’t a bad deal).
There’s nothing like a long quite period to give the shorts control of both a board and its stock. Perhaps the few asking for a blog are right and a some words of encouragement could help weak handed longs to hang in there. Then again, if they are ready to sell then why not let them?
This company has product reserves, boat loads of patents, governmental certifications, a small pile of cash and zero debt.
IMHO, it’s the best open ended option play out there with just as much risk as any short term contract. If Antibioticos comes on line next year then folks may hit the jackpot here. If they don’t then the company could be sold for its patents, certifications and even its stock piles and still probably fetch more than today’s price.
Anyone else notice that we have a buyer here gobbling up 20k blocks while the trash talk is increasing. It reminds me a lot of a builder buying up cheap homes in a bad neighborhood right before beginning a big renovation project.
Sentiment: Strong Buy